Azenta (NASDAQ:AZTA) & Bullfrog AI (NASDAQ:BFRG) Head to Head Survey

Azenta (NASDAQ:AZTA) and Bullfrog AI (NASDAQ:BFRG) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings and analyst recommendations.

Insider and Institutional Ownership

99.1% of Azenta shares are owned by institutional investors. Comparatively, 1.0% of Bullfrog AI shares are owned by institutional investors. 10.9% of Azenta shares are owned by insiders. Comparatively, 14.7% of Bullfrog AI shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Azenta and Bullfrog AI, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Azenta	1	2	4	0	2.43
Bullfrog AI	1	1	0	0	1.50

Azenta currently has a consensus price target of $40.40, suggesting a potential upside of 43.62%. Given Azenta’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Azenta is more favorable than Bullfrog AI.

Profitability

This table compares Azenta and Bullfrog AI’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Azenta	-30.49%	1.23%	1.02%
Bullfrog AI	N/A	-217.80%	-174.57%

Risk & Volatility

Azenta has a beta of 1.36, indicating that its share price is 36% more volatile than the S&P 500. Comparatively, Bullfrog AI has a beta of -2.7, indicating that its share price is 370% less volatile than the S&P 500.

Earnings and Valuation

This table compares Azenta and Bullfrog AI”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Azenta	$593.82 million	2.18	-$55.76 million	($3.96)	-7.10
Bullfrog AI	$120,000.00	85.75	-$6.50 million	($0.54)	-1.03

Bullfrog AI has lower revenue, but higher earnings than Azenta. Azenta is trading at a lower price-to-earnings ratio than Bullfrog AI, indicating that it is currently the more affordable of the two stocks.

Summary

Azenta beats Bullfrog AI on 8 of the 14 factors compared between the two stocks.

About Azenta

Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services. The Life Sciences Products segment offers automated cold storage solutions, consumables and instruments, controlled rate thawing devices, and temperature-controlled storage and transportation solutions. This segment also provides sample management solutions, such as consumable vials and tubes, polymerase chain reaction, plates, instruments for supporting workflows, and informatics. The Life Sciences Services segment provides genomic services, that includes gene sequencing and gene synthesis services; and sample repository solutions, such as on-site and off-site sample storage, cold chain logistics, sample transport and collection relocation, bio-processing solutions, disaster recovery and business continuity, and biospecimen procurement services, as well as project management and consulting services for genomic analysis and the management and care of biological samples used in pharmaceutical, biotech, healthcare, clinical, and academic research, and development sectors. It serves a range of life science customers, including pharmaceutical companies, biotechnology companies, biorepositories, and research institutes. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Burlington, Massachusetts.

About Bullfrog AI

Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data. It also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.